Twist Bioscience (TWST) CEO Leproust sells 49,299 shares via 10b5-1 plan
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an exercise-and-sell transaction under a pre-arranged Rule 10b5-1 trading plan. She exercised options to acquire a total of 49,299 shares of common stock at an exercise price of $8.82 per share and sold the same number of shares in open-market transactions.
The sales covered 24,282 shares at a weighted average price of $65.0789 per share, 23,752 shares at $65.2392 per share, and 1,265 shares at $66.2813 per share. After these transactions, she continues to hold 846,872 shares of Twist Bioscience common stock directly, along with remaining employee stock options, including awards exercisable into 64,950 shares at an exercise price of $67.85 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 49,299 shares ($2.78M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
49,299 shs ($3.21M)
Approx. gross sale proceeds
$3.21M
Approx. exercise cost
$435K
Approx. pre-tax spread
$2.78M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 25,017 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,017 | $8.82 | $221K |
| Sale | Common Stock | 23,752 | $65.2392 | $1.55M |
| Sale | Common Stock | 1,265 | $66.2813 | $84K |
| Exercise | Employee Stock Option (right to buy) | 24,282 | $0.00 | $0.00 |
| Exercise | Common Stock | 24,282 | $8.82 | $214K |
| Sale | Common Stock | 24,282 | $65.0789 | $1.58M |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 273,785 shares (Direct);
Common Stock — 846,872 shares (Direct)
Footnotes (9)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
- F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.505 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.09 to $66.72 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F6. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F7. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F8. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
- F9. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Key Figures
Net shares sold: 49,299 shares
Option exercise price: $8.82 per share
Sale price tranche 1: $65.0789 per share
+4 more
7 metrics
Net shares sold
49,299 shares
Open-market sales reported for late May 2026
Option exercise price
$8.82 per share
Exercise price for 49,299 common shares
Sale price tranche 1
$65.0789 per share
Weighted average for 24,282 shares sold
Sale price tranche 2
$65.2392 per share
Weighted average for 23,752 shares sold
Sale price tranche 3
$66.2813 per share
Weighted average for 1,265 shares sold
Shares held after transactions
846,872 shares
Direct Twist Bioscience common stock holding
Remaining option award
64,950 shares at $67.85
Employee stock option, expires August 31, 2030
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average sales price per share, performance stock options
4 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)""
performance stock options financial
"Represents performance stock options granted to the reporting person on September 1, 2020..."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Twist Bioscience (TWST) CEO Emily Leproust report in this Form 4?
Emily Leproust reported option exercises and related stock sales. She exercised options for 49,299 common shares at an $8.82 exercise price and sold the same 49,299 shares in open-market transactions at weighted average prices around the mid-$60s per share.
Were the Twist Bioscience (TWST) CEO’s stock sales made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on May 27, 2025. Such pre-arranged plans execute trades automatically according to preset instructions, reducing the significance of trade timing decisions.
What stock options does the Twist Bioscience (TWST) CEO still hold after this Form 4?
The derivative holdings table shows remaining employee stock options, including an award exercisable into 64,950 common shares at a $67.85 exercise price expiring August 31, 2030, along with other options that currently show no underlying shares in this filing excerpt.
What type of insider transaction pattern does this Twist Bioscience (TWST) Form 4 show?
The filing reflects an exercise-and-sell pattern. Emily Leproust exercised options to acquire 49,299 shares at $8.82 per share, then sold the same number in open-market trades, resulting in net share sales while retaining a substantial remaining equity position.